Medinet Co

Japan
Kahoku, Ishikawa, Japan, 222-0033

Company profile

Medinet Co company profile

Cancer immuno-cell therapy is an advanced medical practice, which requires advanced knowledge in biotechnology and molecular genetics, specific technical know-how, professional cell-engineers, dedicated-use facilities with advanced safety control, particular materials and a custom-made management system for cell-culturing schedule. However, it is difficult for medical institutions to meet all of these requirements on the financial and technical aspects, and only limited numbers of medical institutions, such as university hospitals, are able to fulfill such requirements. Such limited numbers of medical institutions perform the immuno-cell therapy to limited number of patients for research purpose only. Therefore, it seemed that the immuno-cell therapy had not been widely used in clinical practice. In order to make the immuno-cell therapy widely available to anyone who wish to receive, MEDINET created and started providing a comprehensive solution, which includes technical know-how, facilities, systems, materials, professional cell-engineers, and other requirements to conduct immuno-cell therapy, to medical institutions.

Business identity

Phone number
+81454780041
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
1995-01-01, Year

Headquarters

Postal code
222-0033
Country code
JP
Continent
Asia

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
1
Total equity funding
$4.3M
Last funding
Post IPO Equity / $4.3M / 2015-09-29
Last equity funding
Post IPO Equity / $4.3M
Investors
1
Lead investors
1
Founders
1
Exited on
2003-10-08

Founders and investors

Founders

Kohji Egawa

Lead investors

Whiz Partners

Investors

Whiz Partners